Mainz Biomed (NASDAQ:MYNZ) vs. Palladyne AI (NASDAQ:PDYN) Financial Analysis

Palladyne AI (NASDAQ:PDYN) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Risk & Volatility

Palladyne AI has a beta of 3.67, suggesting that its stock price is 267% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Palladyne AI and Mainz Biomed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palladyne AI	1	2	3	0	2.33
Mainz Biomed	1	1	0	0	1.50

Palladyne AI presently has a consensus target price of $11.00, suggesting a potential upside of 93.66%. Given Palladyne AI’s stronger consensus rating and higher possible upside, analysts plainly believe Palladyne AI is more favorable than Mainz Biomed.

Earnings and Valuation

This table compares Palladyne AI and Mainz Biomed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palladyne AI	$5.25 million	53.38	$10.04 million	($0.68)	-8.35
Mainz Biomed	$659,935.00	21.97	-$21.65 million	($65.60)	-0.02

Palladyne AI has higher revenue and earnings than Mainz Biomed. Palladyne AI is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Palladyne AI and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palladyne AI	-254.75%	-53.29%	-40.05%
Mainz Biomed	N/A	N/A	N/A

Insider and Institutional Ownership

26.0% of Palladyne AI shares are owned by institutional investors. 13.4% of Palladyne AI shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Palladyne AI beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

About Palladyne AI

Palladyne AI Corp., a software company, focuses on delivering software that enhances the utility and functionality of third-party stationary and mobile robotic systems in the United States. Its Artificial Intelligence (AI)/ Machine Learning (ML) software platform enables robots to observe, learn, reason, and act in structured and unstructured environments. The company's software platform enables robotic systems to perceive their environment and quickly adapt to changing circumstances by generalizing from their experience using dynamic real-time operations without extensive programming and with minimal robot training. It serves customers from various industries, such as industrial manufacturing, warehousing and logistics, defense, infrastructure maintenance and repair, energy, aerospace and aviation, and others. The company was formerly known as Sarcos Technology and Robotics Corporation and changed its name to Palladyne AI Corp. in March 2024. Palladyne AI Corp. was founded in 2017 and is headquartered in Salt Lake City, Utah.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.